Amgen Inc. Equity-NMS: AMGN

Healthcare

Drug Manufacturers - General

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :	$325.31
Open :	$324.82
Today's high :	$327.34
Today's low :	$323.02
52W low :	$245.3149
52W high :	$346.38
1Y :	20.54%
5Y :	40.79%
EPS(TTM): :	12.93
Shares O/S :	538.48 M
Market cap :	175.94 B

What is the share price of Amgen Inc. today?

Amgen Inc. (AMGN) share price as of December 17, 2025, is $326.74. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Amgen Inc.?

Yes, Indian Investors can invest in the Amgen Inc. (AMGN) Share by opening an international trading account with Angel One.

How can I purchase Amgen Inc. shares in India?

Purchasing Amgen Inc. (AMGN) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Amgen Inc. (AMGN) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Amgen Inc.?

Yes, you can purchase fractional shares of Amgen Inc. (AMGN) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Amgen Inc.?

The market capitalization of Amgen Inc. on December 17, 2025, is $175.94 B.

In which sector Amgen Inc. belongs?

Amgen Inc. operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.

What documents are required to invest in Amgen Inc. stocks?

In order to invest in Amgen Inc. (AMGN) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.